Literature DB >> 17272323

International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII.

Tomohiro Matsuda1, Tomomi Marugame.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17272323     DOI： 10.1093/jjco/hyl158

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN： 0368-2811            Impact factor:   3.019


× No keyword cloud information.
  8 in total

1.  The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine.

Authors:  Qiwei Li; Xiaobin Yin; Wei Wang; Ming Zhan; Benpeng Zhao; Zhaoyuan Hou; Jian Wang
Journal:  Oncol Lett       Date:  2015-11-06       Impact factor: 2.967

2.  Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea.

Authors:  Ban Seok Lee; Eun-Cheol Park; Seung Woo Park; Chung Mo Nam; Jaehoon Roh
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

3.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

4.  Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case report.

Authors:  Tokuhiro Matsubara; Tsutomu Nishida; Yoshito Tomimaru; Masashi Yamamoto; Shiro Hayashi; Sachiko Nakajima; Koji Fukui; Keizo Dono; Shiro Adachi; Tatsuya Ioka; Masashi Kanai; Masami Inada
Journal:  Mol Clin Oncol       Date:  2016-10-26

5.  High Response Rate and Prolonged Survival of Unresectable Biliary Tract Cancer Treated With a New Combination Therapy Consisting of Intraarterial Chemotherapy Plus Radiotherapy.

Authors:  Takuma Goto; Hiroya Saito; Junpei Sasajima; Toru Kawamoto; Akihiro Fujinaga; Tatsuya Utsumi; Nubuyuki Yanagawa; Kazuhide Hiramatsu; Akio Takamura; Hiroki Sato; Shugo Fujibayashi; Mikihiro Fujiya
Journal:  Front Oncol       Date:  2020-11-17       Impact factor: 6.244

6.  Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.

Authors:  Akihiro Murata; Ryosuke Amano; Nobuya Yamada; Kenjiro Kimura; Masakazu Yashiro; Bunzo Nakata; Kosei Hirakawa
Journal:  World J Surg Oncol       Date:  2013-05-27       Impact factor: 2.754

7.  A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.

Authors:  Eiichiro Suzuki; Masafumi Ikeda; Takuji Okusaka; Shoji Nakamori; Shinichi Ohkawa; Tatsuya Nagakawa; Narikazu Boku; Hiroaki Yanagimoto; Tosiya Sato; Junji Furuse
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-24       Impact factor: 3.333

8.  Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1.

Authors:  Qiwei Li; Ming Zhan; Wei Chen; Benpeng Zhao; Kai Yang; Jie Yang; Jing Yi; Qihong Huang; Man Mohan; Zhaoyuan Hou; Jian Wang
Journal:  Oncotarget       Date:  2016-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.